At 10 a.m. on June 6, 2022, Huanyu Bio held a grand press conference at the Jiangzhou International Conference Center.

In the past year, Universal Biotech has held a press conference every few days, and each time is a major breakthrough in medicine or technological innovation.

Because of this, as soon as the news was released, countless reporters from home and abroad flocked to us, and thousands of reporters occupied the huge press room.

Lin Wei, vice president and chief press officer of Universal Biotech, chaired the press conference.

Under the attention of countless reporters, Lin Wei said excitedly: "Good morning, all kinds of guests, journalists and friends, welcome to participate in the press conference of the world..."

KAKAKA!!!

Just as Lin Wei spoke, the publishing hall instantly became a sea of ​​spotlights.

Lin Wei paused for a moment and said, "I want to tell you a good news here. Under the leadership of Zhou Wen, chief scientist of Universal Biology, senior engineer Lin Ming, and Academician He Junfeng, deputy director and chief scientist of the Institute of Hepatitis B of the Chinese Academy of Sciences, and with the continuous efforts of hundreds of other scientific researchers, we have successfully conquered viral hepatitis B!"

The press conference scene was a little quiet at the beginning, but the next second, a huge buzzing sound broke out on the scene.

"What does it mean? Have you developed a new drug?"

"I can't understand this, conquering it means healing!"

"It's impossible, isn't hepatitis B virus impossible to cure it."

"Then I don't know..."

Lin Wei gave the on-site reporters more than ten seconds to digest what he had just said, and then explained their research results.

When the reporter on the scene learned that this drug would cure nearly 300 million hepatitis B virus patients around the world, heated discussions broke out.

...

The news that the hepatitis B virus was conquered instantly spread to countries around the world.

Countless hepatitis B patients were naturally extremely excited when they saw this news.

However, some of the dozen pharmaceutical companies that are studying new hepatitis B drugs and have even entered the clinical trial stage, were immediately struck by lightning after hearing this news.

Especially those six pharmaceutical companies that obtained data on Universal Bio's formulas, they spent so much energy to do this, but they all did useless work in the end.

...

In the inner ring of Kyoto, inside a building with the national emblem hanging.

A man with a national face was reading an internal journalism news and soon read the news.

He showed a slightly surprised look on his face and asked in a deep voice: "Is this news true?"

The confidential secretary who was sorting out the information next to him immediately said respectfully: "Yes, the head of the drug administration has tested it with DGD technology, it's true."

The man with a national face nodded, and a smile appeared on his serious face, and said with a smile: "No wonder he dared to promise me. It seems that he was prepared for it!"

The confidential secretary smiled and said, "Yes! Professor Zhou's level in the field of medicine is indeed worthy of the word "miracle doctor."

It goes without saying how important DGD technology is to pharmaceutical companies. It can be regarded as one of the greatest inventions in the pharmaceutical industry. Such high-end and sophisticated technology cannot be disclosed as long as it wants. It must obtain the consent of the national level.

The same is true for European and American countries. European and American companies' technology cannot be exported to China casually.

So it is conceivable how fierce opposition was encountered when Universal Biotech proposed to share DGD technology?

Including many upper-level bosses who trust Zhou Wen very much, they also have objections.

However, Zhou Wen still convinced a group of big shots.

Zhou Wen has a very good reason. Although DGD technology is important, it is far from enough to regain the standards of the global pharmaceutical market.

First of all, NMPA has always been the leader of the FDA, and the freezing three feet of ice is not a day. It is not enough to completely reverse this situation in just one day or two days.

Because there are many interests involved.

If there is interests, there will be disputes. Many people are unwilling to leave their comfort zones and explore unknown areas. If they do well, the credit will be the leader. If they do not do well, or make mistakes, the specific person in charge will be unlucky. Therefore, the promotion of DGD technology in China has encountered great resistance.

Second and most important point, European and American countries will definitely not allow core technologies to be implemented by Chinese companies in their own country. Even if the academic community supports it, it will be useless to promote it by pharmaceutical companies.

There is no need to think about this at all.

Then the question arises. Even if China's NMPA adopts DGD technical standards, if the drugs developed by Universal Biotechnology want to be sold abroad, it still needs to go through the time-consuming and lengthy clinical trial procedures again.

Some people may say that it is their business for European and American countries to be willing to be self-proclaimed, and at worst it can be sold domestically.

But Zhou Wen couldn't wait. His new drug development speed was far beyond the imagination of ordinary people. He held a handful of new drugs in his hand and needed to be launched on the market. The lengthy clinical trial time has caused the drug to be unable to be launched as quickly as drug cosmetic hair germinants, scar removal creams, and wrinkle removal creams.

And DGD technology is the stepping stone to open up the European and American pharmaceutical markets.

With the speed of Zhou Wen's drug development, European and American pharmaceutical companies are not enough for him to fight.

Therefore, sharing DGD technology with Europe and the United States is not convenient for European and American countries, but for themselves.

Of course, these are unaware of.

The reason why the upper-level leader agreed to Zhou Wen was only because of his medical skills.

Zhou Wen's medical skills have almost reached the point of being superb. The saints of national medicine have not been enough to describe him. The bosses and their families are now calling him "miracle doctors".

You can imagine how important his words are?

Therefore, when he patted his chest and assured all the leaders that he would earn back DGD technology with capital and profit, all the leaders finally agreed to his suggestions.

Now it seems that Zhou Wen has prepared his trump card!

...

...

Half a month later.

"Qingganling Preparation" developed by Huanyu Bio, code-named PD0079, and the second-class new drugs of four or five other pharmaceutical companies, have become the first batch of experimental subjects of DGD technology in China and conducted phase one clinical trials.

It usually takes 3 to 6 months to phase one clinical trial. After using DGD technology, the trial was completed in just one week.

Of course, "Qinggan Ling Preparation" passed the first phase of clinical trial without any surprise.

As soon as the news came out, it caused a huge sensation.

Countless pharmaceutical laboratories and pharmaceutical companies are surprised and envious of the rapid and efficient DGD technology.

Relevant departments of European, American, Japanese and Korean companies have also accelerated the approval of DGD technology.

Soon, Hanguo became the second country to adopt DGD technology.

Ribenzene followed closely behind.

Then there are Germany, Portugal, France, Italy, Russia...

At this speed like a competition, "Qinggan Ling Preparation" has passed the second phase of clinical trial.

Everything is ready...
Chapter completed!